ProArc Medical Ltd.
- Industry
- Medical Devices & Equipment
- Founded Year
- 2010
- Headquarters
- Hayetsira 13, Yokneam Illit, Israel
- Employee Count
- 0
Key People
- Shay Geller - CEO
- Dr. Yair Feld - Founder & Chief Medical Officer
Assessment
- Team
-
Aspect: First-time physician innovator
Summary: The leadership team includes a first-time physician innovator.
The team is led by a first-time physician innovator, which may present challenges in navigating the complexities of the MedTech industry.
- Clinical Need
-
Aspect: Very Strong
Summary: BPH is a prevalent condition with significant unmet needs.
Benign Prostatic Hyperplasia (BPH) affects a large aging male population, creating a substantial demand for effective and minimally invasive treatment options.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The BPH treatment market is highly competitive with major players.
The market includes established companies like Boston Scientific and Olympus, making it challenging for new entrants to gain significant market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing minimally invasive BPH treatments involves moderate technical challenges.
While the development of minimally invasive devices is complex, existing technologies provide a foundation, reducing the overall technical risk.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents but lacks granted ones.
Pending patents indicate innovation but also pose risks if not granted, potentially affecting the company's competitive edge.
- Financing
-
Aspect: Medium
Summary: The company has secured moderate funding from venture capital.
Funding from investors like Pontifax Venture Capital provides resources for development but may not suffice for large-scale commercialization.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The product is undergoing pivotal trials.
Pivotal trials are crucial for regulatory approval; however, they are time-consuming and carry the risk of unfavorable outcomes.
Opportunity Rollup
- Odds of Success
- 3.3
- Peak Market Share
- 4.5
- Segment CAGR
- 5.9%
- Market Segment
- Nephrology and Urology Devices
- Market Sub Segment
- Benign Prostatic Hyperplasia Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.68 |
| 3 | 1.58 |
| 4 | 3.15 |
| 5 | 4.50 |
Key Takeaway
ProArc Medical Ltd. addresses a significant clinical need in the BPH treatment market but faces challenges due to intense competition and regulatory hurdles.